Insmed Inc. (INSM)
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $1.42 per share a year ago.
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
Options Bulls Could Be Right About This Pharma Stock
Insmed Inc (NASDAQ:INSM) shares were last seen up 0.3% to trade at $164.03, after a price-target hike to $237 from $231 at Barclays.
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
Insmed (INSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Insmed CEO reveals Japan patient population exceeds US market for lung disease
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the entire United States.
Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well
Insmed (INSM) remains a "Strong Buy", driven by positive phase 3b ENCORE results for ARIKAYCE in 1st-line MAC lung disease and robust pipeline progress. INSM is positioned to expand ARIKAYCE's label to 1st-line MAC patients [200k+], convert accelerated to full approval for refractory MAC, and pursue Japanese label expansion. BRINSUPRI is approved for non-cystic fibrosis bronchiectasis, with 2026 revenue guidance of at least $1 billion; ARIKAYCE 2025 sales reached $433.8 million, up 19% YoY.
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study
Insmed stock jumps as Arikayce meets key goals in a late-stage study, paving the way for label expansion and a major boost to its potential market.
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript
Insmed shares rise on positive late-stage trial results for lung disease therapy
Insmed Incorporated (NASDAQ:INSM) shares jumped almost 8% in early trade on Monday after the company reported positive topline results from a Phase 3b study evaluating its lung disease therapy ARIKAYCE. The ENCORE trial assessed ARIKAYCE (amikacin liposome inhalation suspension) in combination with standard multidrug therapy versus placebo plus multidrug therapy in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection who had not previously received antibiotics.
